Last year, a widely publicized report by Case Western researchers suggested the cancer drug Targretin could be useful for treating AD. Now, studies by four independent academic teams have failed to replicate some aspects of the original work, but the main conclusions - that Targretin reduces levels of soluble beta-amyloid and improves cognitive function in mice - appear to stand.